

# Anti-IL-18 Reference Antibody (Camoteskimab)

Recombinant Antibody  
Catalog # APR10064

## Product Information

---

<b>Application</b>	FC, Kinetics, Animal Model
<b>Primary Accession</b>	<a href="#">Q14116</a>
<b>Reactivity</b>	Human
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1
<b>Calculated MW</b>	22326

## Additional Information

---

<b>Target/Specificity</b>	IL-18
<b>Endotoxin Conjugation</b>	Unconjugated
<b>Expression system</b>	CHO Cell
<b>Format</b>	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

## Protein Information

---


<b>Name</b>	IL18 ( <a href="#">HGNC:5986</a> )
<b>Synonyms</b>	IGIF, IL1F4
<b>Function</b>	Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses (PubMed: <a href="#">10653850</a> ). Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators (PubMed: <a href="#">14528293</a> , PubMed: <a href="#">25500532</a> , PubMed: <a href="#">37993714</a> ). Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells (PubMed: <a href="#">10653850</a> ). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed: <a href="#">33883744</a> ).
<b>Cellular Location</b>	Cytoplasm, cytosol. Secreted. Note=The precursor is cytosolic (PubMed: <a href="#">33883744</a> ). In response to inflammasome-activating signals, cleaved and secreted (PubMed: <a href="#">33883744</a> , PubMed: <a href="#">37993712</a> , PubMed: <a href="#">37993714</a> ). Mature form is secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed: <a href="#">33883744</a> , PubMed: <a href="#">37993714</a> ). In contrast, the precursor form is not released, due to

the presence of an acidic region that is proteolytically removed by CASP1, CASP4 or CASP5 during maturation (PubMed:33883744, PubMed:37993714). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10 (PubMed:32272059).


## Tissue Location

[Isoform 2]: Expressed in ovarian carcinoma but undetectable in normal ovarian epithelial cells. Resistant to proteolytic activation by caspase-1 and -4


## Images




Anti-IL-18 Reference Antibody (Camoteskimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-18 Reference Antibody (Camoteskimab) is more than 98.41%, determined by SEC-HPLC.



Immobilized human IL 18 C His at 2 µg/mL can bind Anti-IL-18 Reference Antibody (Camoteskimab),  $EC_{50}=0.0126 \mu\text{g/mL}$



Anti-IL-18 Reference Antibody (Camoteskimab)-induced FACS Blocking activity was evaluated using Hu IL-18R $\alpha$ &IL-18R $\beta$  HEK293-. The  $IC_{50}$  was approximately 0.172 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.